株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

人工血液:世界市場

Artificial Blood: Global Markets to 2027

発行 BCC Research 商品コード 619846
出版日 ページ情報 英文 240 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.28円で換算しております。
Back to Top
人工血液:世界市場 Artificial Blood: Global Markets to 2027
出版日: 2018年03月28日 ページ情報: 英文 240 Pages
概要

世界における人工血液の市場規模は、2022年に62億米ドル、2027年には156億米ドルへ達すると予測され、2022年から2027年の予測期間中は20.5%のCAGR (年間複合成長率) が見込まれています。

当レポートでは、世界の人工血液市場について調査し、市場の概要と動向、ソース・種類・用途・地域別の分析、特許動向、市場機会、および主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場概要

  • イントロダクション
  • ヒト血液に問題はあるか?
  • 人工血液に対する新たなニーズ
  • 人工血液製品の開発における障壁
  • 人工血液の理想的な特徴
  • ヒト血液に勝る人工血液
  • 人工血液開発における課題

第4章 市場推計

  • 市場ダイナミクス:要因・影響分析
  • 世界の潜在的市場
  • 市場普及

第5章 市場:ソース別

  • イントロダクション
  • ヒト血液から開発される人工血液
  • 動物血液から開発される人工血液
  • 組み換え技術を用いて開発される人工血液
  • 表面修飾ヘモグロビン
  • クロスリンクヘモグロビン
  • 重合ヘモグロビン

第6章 市場:種類別

  • イントロダクション
  • パーフルオロカーボン乳剤
  • ヘモグロビン系酸素担体

第7章 市場分析:用途別

  • イントロダクション
  • 世界の潜在的人工血液市場:用途別

第8章 市場分析:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • その他 (ROW)

第9章 規制・特許レビュー

  • イントロダクション
  • FDA規制
  • FDA適正製造基準 (GMP) ・レポーティング
  • 特許レビュー

第10章 競合情勢

  • イントロダクション

第11章 製品分析

  • イントロダクション
  • Hemolink
  • HemAssist
  • HemoSpan
  • HemoTech
  • DDFPe
  • Oxycyte
  • Oxygent
  • Vidaphor
  • PHER-O2
  • Polyheme
  • Sanguinate

第12章 企業プロファイル

付録

BCC Research について

図表

List of Tables

  • Summary Table: Global Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 1: Historical Events Related to Blood Transfusion
    • Table 2: Potential Benefits and Application Areas of Artificial Blood
    • Table 3: The Challenges Associated with the Development of Artificial Blood
    • Table 4: Average Number of Blood Units Required During Particular Medical Condition
    • Table 5: Market Penetration Cases Based on Set of Assumptions
    • Table 6: Global Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 7: Sources of Hemoglobin Molecules Used to Prepare Free Hemoglobin Solutions
    • Table 8: Pros and Cons of Artificial Blood Developed from Human Blood
    • Table 9: Pros and Cons of Artificial Blood Developed from Animal Blood
    • Table 10: Pros & Cons of Artificial Blood Developed from Recombinant Blood
    • Table 11: Summary of Acellular Hb-Based Oxygen Carriers
    • Table 12: Hemoglobin Based Oxygen Carrier Products and Approval Status
    • Table 13: Potential Clinical Applications of Oxygen Carriers
    • Table 14: Composition of PFC Emulsion Based Artificial Blood Products
    • Table 15: First-Generation Perfluorocarbon Emulsions Used in Medicine and Biology
    • Table 16: Comparative Study of Second-Generation PFCs
    • Table 17: PFC Emulsion Products and Current Status
    • Table 18: Comparative Study Between RBCs and HBOCs
    • Table 19: HBOC Solutions Transfusion: Side Effects and Possible Causes
    • Table 20: HBOC Products Developed by Various Companies
    • Table 21: Global Potential Artificial Blood Market, by Application, Through 2027 ($ Millions)
    • Table 22: United States: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 23: Canada: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 24: Mexico: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 25: Germany: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 26: France: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 27: U.K.: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 28: Italy: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 29: Spain: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 30: Russia: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 31: China: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 32: India: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 33: Japan: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 34: Australia: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 35: Brazil: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 36: South Africa: Potential Artificial Blood Market, Through 2027 ($ Millions)
    • Table 37: Summary of Three Clinical Trial Phases Recognized by FDA
    • Table 38: Hemolink: Raw Material and Method Overview
    • Table 39: Hemolink: Advantages and Disadvantages
    • Table 40: Hemolink Clinical Trials Details
    • Table 41: Hemolink Clinical Trial: Tracking Information
    • Table 42: Hemolink Clinical Trial: Descriptive Information
    • Table 43: Hemolink Clinical Trial: Recruitment Information
    • Table 44: Hemolink Clinical Trial: Administrative Information
    • Table 45: HemAssist: Raw Material and Method Overview
    • Table 46: HemAssist: Product Characteristics
    • Table 47: HemAssist: Advantages and Disadvantages
    • Table 48: Hemopure: Raw Material and Method Overview
    • Table 49: Hemopure: Product Characteristics
    • Table 50: Hemopure: Advantages and Disadvantages
    • Table 51: Hemopure: List of Clinical Trials Registered
    • Table 52: Hemopure Clinical Trial: Patient Information
    • Table 53: Hemopure Clinical Trial: Details
    • Table 54: Summary of the Red-Blood-Cell-Controlled Phase 2 and Phase 3 Clinical Trial Performed by Biopure Corp.
    • Table 55: Red-Blood-Cell-Controlled Clinical Trial Performed on Surgical Patients, by Dosage and Effects
    • Table 56: Hemopure Clinical Trial: Tracking Information
    • Table 57: Decriptive Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia
    • Table 58: Recruitment Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia
    • Table 59: Administrative Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia
    • Table 60: A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects
    • Table 61: Descriptive Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects
    • Table 62: Recruitment Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects
    • Table 63: Administrative Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects
    • Table 64: Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia
    • Table 65: Tracking Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia
    • Table 66: Descriptive Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia
    • Table 67: Recruitment Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia
    • Table 68: Administrative Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia
    • Table 69: Hemospan: Raw Material and Method Overview
    • Table 70: Hemospan: Product Characteristics
    • Table 71: Hemospan: Advantages and Disadvantages
    • Table 72: Clinical Studies with Hemospan: Completed and Ongoing
    • Table 73: Hemospan Clinical Trial: Details
    • Table 74: Hemospan Clinical Trial: Tracking Information
    • Table 75: Hemospan Clinical Trial: Descriptive Information
    • Table 76: Hemospan Clinical Trial: Recruitment Information
    • Table 77: Hemospan Clinical Trial: Administrative Information
    • Table 78: Hemotech: Raw Material and Method Overview
    • Table 79: HemoTech: Advantages and Disadvantages
    • Table 80: HemoTech Clinical Trials: Details
    • Table 81: HemoTech Clinical Trial: Tracking Information
    • Table 82: HemoTech Clinical Trial: Descriptive Information
    • Table 83: HemoTech Clinical Trial: Recruitment Information
    • Table 84: HemoTech Clinical Trial: Administrative Information
    • Table 85: DDFPe: Company Product Range and Description
    • Table 86: DDFPe: Raw Material and Method Overview
    • Table 87: DDFPe: Advantages and Disadvantages
    • Table 88: DDFPeClinical Trials: Details
    • Table 89: DDFPe Clinical Trial: Tracking Information
    • Table 90: DDFPe Clinical Trial: Descriptive Information
    • Table 91: DDFPe Clinical Trial: Recruitment Information
    • Table 92: DDFPe Clinical Trial: Administrative Information
    • Table 93: Oxycyte: Raw Material and Method Overview
    • Table 94: Oxycyte: Advantages and Disadvantages
    • Table 95: Oxycyte Clinical Trials: Details
    • Table 96: Oxycyte Clinical Trial: Tracking Information
    • Table 97: Descriptive Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI)
    • Table 98: Recruitment Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI)
    • Table 99: Administrative Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI)
    • Table 100: Details of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
    • Table 101: Tracking Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
    • Table 102: Descriptive Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
    • Table 103: Recruitment Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
    • Table 104: Administrative Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
    • Table 105: Oxygent: Raw Material and Method Overview
    • Table 106: Oxygent: Advantages and Disadvantages
    • Table 107: Oxygent: Clinical Trials
    • Table 108: Vidaphor: Raw Material and Method Overview
    • Table 109: Vidaphor: Advantages and Disadvantages
    • Table 110: Vidaphor: Clinical Trial
    • Table 111: PHER-O2: Raw Material and Method Overview
    • Table 112: PHER-O2: Advantages and Disadvantages
    • Table 113: PHER-O2: Clinical Trials
    • Table 114: PolyHeme: Raw Material and Method Overview
    • Table 115: PolyHeme: Product Characteristics
    • Table 116: PolyHeme: Advantages and Disadvantages
    • Table 117: Polyheme Clinical Trials: Patient Information
    • Table 118: PolyHeme Clinical Trial: Details
    • Table 119: PolyHeme Clinical Trial: Tracking Information
    • Table 120: PolyHeme Clinical Trial: Descriptive Information
    • Table 121: PolyHeme Clinical Trial: Recruitment Information
    • Table 122: PolyHeme Clinical Trial: Administrative Information
    • Table 123: Sanguinate: Raw Material and Method Overview
    • Table 124: Sanguinate: Advantages and Disadvantages
    • Table 125: Sanguinate: Clinical Trials
    • Table 126: Sanguinate Clinical Trial: Details
    • Table 127: Sanguinate Clinical Trial: Tracking Information
    • Table 128: Sanguinate Clinical Trial: Descriptive Information
    • Table 129: Sanguinate Clinical Trial: Recruitment Information
    • Table 130: Sanguinate Clinical Trial: Administrative Information
    • Table 131: Alliance Pharmaceutical Corp: Company and Product Snapshot
    • Table 132: Baxter International Inc.: Company and Product Snapshot
    • Table 133: Biopure Corp: Company and Product Snapshot
    • Table 134: FluorO2 Therapeutics Inc.: Company and Product Snapshot
    • Table 135: HemoBioTech, Inc.: Company and Product Snapshot
    • Table 136: HemoBioTech, Inc.: Company and Product Snapshot
    • Table 137: Northfield Laboratories Inc.: Company and Product Snapshot
    • Table 138: Prolong Pharmaceuticals, LLC: Company and Product Snapshot
    • Table 139: Sangart, Inc: Company and Product Snapshot
    • Table 140: Sanguine Biosciences: Company and Product Snapshot
    • Table 141: Tenax Therapeutics, Inc.: Company and Product Snapshot
    • Table 142: Therapure Biopharma Inc.: Company and Product Snapshot
    • Table 143: Abbreviations Used in Artificial Blood Market

List of Figures

  • Summary Figure: Global Potential Artificial Blood Market, 2022-2027 ($ Millions)
    • Figure 1: Medical Applications of Human Red Blood Cells
    • Figure 2: Total Number of Surgeries and Death Cases in the World, 2017-2022 (Thousands)
    • Figure 3: Total Number of Blood Units Transfused in the World, 2017-2027 (Millions)
    • Figure 4: Global Potential Artificial Blood Market, 2022-2027 ($ Millions)
    • Figure 5: Artificial Blood Manufactured from Different Sources
    • Figure 6: Historical Events of HBOCs Developed Using Recombinant Technology
    • Figure 7: Classification of Modified Hemoglobin Solution Based on Methods
    • Figure 8: Classification of Different Types of Oxygen Carriers
    • Figure 9: Generations of Perfluorocarbon Emulsions
    • Figure 10: Advantages and Disadvantages of PFC Emulsions
    • Figure 11: Development of HBOCs
    • Figure 12: Advantages and Disadvantages of HBOCs
    • Figure 13: Global Potential Artificial Blood Market, by Application, 2022-2027 ($ Millions)
    • Figure 14: United States: Country Snapshot
    • Figure 15: Heart Disease Trend in the United States
    • Figure 16: Cancer Disease Trend in the United States
    • Figure 17: Transport Accident Trend in the United States
    • Figure 18: Blood Supply in the United States
    • Figure 19: Blood Demand in the United States
    • Figure 20: United States: Potential Artificial Blood Market, 2022-2027 (Millions)
    • Figure 21: Canada: Country Snapshot
    • Figure 22: Heart Disease Trend in Canada
    • Figure 23: Cancer Disease Trend in Canada
    • Figure 24: Transport Accident Trend in Canada
    • Figure 25: Blood Supply in Canada
    • Figure 26: Blood Demand in Canada
    • Figure 27: Canada: Potential Artificial Blood Market, 2022-2027 (Millions)
    • Figure 28: Mexico: Country Snapshot
    • Figure 29: Heart Disease Trend in Mexico
    • Figure 30: Cancer Disease Trend in Mexico
    • Figure 31: Transport Accident Trend in Mexico
    • Figure 32: Blood Supply in Mexico
    • Figure 33: Blood Demand in Mexico
    • Figure 34: Mexico: Potential Artificial Blood Market, 2022-2027 (Millions)
    • Figure 35: Germany: Country Snapshot
    • Figure 36: Heart Disease Trend in Germany
    • Figure 37: Cancer Disease Trend in Germany
    • Figure 38: Transport Accident Trend in Germany
    • Figure 39: Blood Supply in Germany
    • Figure 40: Blood Demand in Germany
    • Figure 41: Germany: Potential Artificial Blood Market, 2022-2027 ($ Millions)
    • Figure 42: France: Country Snapshot
    • Figure 43: Heart Disease Trend in France
    • Figure 44: Cancer Disease Trend in France
    • Figure 45: Transport Accident Trend in France
    • Figure 46: Blood Supply in France
    • Figure 47: Blood Demand (RBCs Transfused) in France
    • Figure 48: France: Potential Artificial Blood Market, 2022-2027 ($ Millions)
    • Figure 49: United Kingdom: Country Snapshot
    • Figure 50: Heart Disease Trend in the U.K.
    • Figure 51: Cancer Disease Trend in the U.K.
    • Figure 52: Transport Accident Trend in the U.K
    • Figure 53: Blood Supply in the U.K.
    • Figure 54: Blood Demand in the U.K.
    • Figure 55: U.K.: Potential Artificial Blood Market, 2022-2027 ($ Millions)
    • Figure 56: Italy: Country Snapshot
    • Figure 57: Heart Disease Trend in Italy
    • Figure 58: Cancer Disease Trend in Italy
    • Figure 59: Transport Accident Trend in Italy
    • Figure 60: Blood Supply in Italy
    • Figure 61: Blood Demand in Italy
    • Figure 62: Italy: Potential Artificial Blood Market, 2022-2027 ($ Millions)
    • Figure 63: Spain: Country Snapshot
    • Figure 64: Heart Disease Trend in Spain
    • Figure 65: Cancer Disease Trend in Spain
    • Figure 66: Transport Accident Trend in Spain
    • Figure 67: Blood Supply in Spain
    • Figure 68: Blood Demand in Spain
    • Figure 69: Spain: Potential Artificial Blood Market, 2022-2027 ($ Millions)
    • Figure 70: Russia: Country Snapshot
    • Figure 71: Heart Disease Trend in Russia
    • Figure 72: Cancer Disease Trend in Russia
    • Figure 73: Transport Accident Trend in Russia
    • Figure 74: Blood Supply in Russia
    • Figure 75: Blood Demand in Russia
    • Figure 76: Russia: Potential Artificial Blood Market, 2022-2027 ($ Millions)
    • Figure 77: China: Country Snapshot
    • Figure 78: Heart Disease Trend in China
    • Figure 79: Cancer Disease Trend in China
    • Figure 80: Transport Accident Trend in China
    • Figure 81: Blood Supply in China
    • Figure 82: Blood Demand in China
    • Figure 83: China: Potential Artificial Blood Market, 2022-2027 ($ Millions)
    • Figure 84: India: Country Snapshot
    • Figure 85: Heart Disease Trend in India
    • Figure 86: Cancer Disease Trend in India
    • Figure 87: Transport Accident Trend in India
    • Figure 88: Blood Supply in India
    • Figure 89: Blood Demand in India
    • Figure 90: India: Potential Artificial Blood Market, 2022-2027 (Millions)
    • Figure 91: Japan: Country Snapshot
    • Figure 92: Heart Disease Trend in Japan
    • Figure 93: Cancer Disease Trend in Japan
    • Figure 94: Transport Accident Trend in Japan
    • Figure 95: Blood Supply in Japan
    • Figure 96: Blood Demand in Japan
    • Figure 97: Japan: Potential Artificial Blood Market, 2022-2027 (Millions)
    • Figure 98: Australia: Country Snapshot
    • Figure 99: Heart Disease Trend in Australia
    • Figure 100: Cancer Disease Trend in Australia
    • Figure 101: Transport Accident Trend in Australia
    • Figure 102: Blood Supply in Australia
    • Figure 103: Blood Demand in Australia
    • Figure 104: Australia: Potential Artificial Blood Market, 2022-2027 (Millions)
    • Figure 105: Brazil: Country Snapshot
    • Figure 106: Heart Disease Trend in Brazil
    • Figure 107: Cancer Disease Trend in Brazil
    • Figure 108: Transport Accident Trend in Brazil
    • Figure 109: Blood Supply in Brazil
    • Figure 110: Blood Demand in Brazil
    • Figure 111: Brazil: Potential Artificial Blood Market, 2022-2027 ($ Millions)
    • Figure 112: South Africa: Country Snapshot
    • Figure 113: Heart Disease Trend in South Africa
    • Figure 114: Cancer Disease Trend in South Africa
    • Figure 115: Transport Accident Trend in South Africa
    • Figure 116: Blood Supply in South Africa
    • Figure 117: Blood Demand in South Africa
    • Figure 118: South Africa: Potential Artificial Blood Market, 2022-2027 ($ Millions)
    • Figure 119: Current Competition in the Global Artificial Blood Market (I), 2020-2022
    • Figure 120: Current Competition in the Global Artificial Blood Market (II), 2022-2027
    • Figure 121: Artificial Blood: Parameters for Product Analysis
    • Figure 122: Hemolink: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
    • Figure 123: HemAssist: Production Flow Chart
    • Figure 124: HemAssist: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
    • Figure 125: Hemopure: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
    • Figure 126: Hemospan: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
    • Figure 127: HemoTech: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
    • Figure 128: DDFPe: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
    • Figure 129: Oxycyte: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
    • Figure 130: Oxygent: Product Analysis (Based on Safety, Effectiveness, Cost, And Legal Implications)
    • Figure 131: Vidaphor: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
    • Figure 132: PHER-O2: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
    • Figure 133: PolyHeme: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
    • Figure 134: Sanguinate: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
目次
Product Code: BIO164A

Report Highlights

The global market for potential artificial blood is estimated to grow from nearly $6.2 billion in 2022 to $15.6 billion by 2027 with a compound annual growth rate (CAGR) of 20.5% for the period of 2022-2027.

Report Includes:

  • 144 tables
  • An overview of global artificial blood market
  • Analyses of global market trends, with estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027
  • Identification of growth-driving factors influencing the artificial blood market, as well as opportunities, restraints, and technological developments
  • Profiles of leading companies in the market, including Alliance Pharmaceutical Corp., Baxter Healthcare Corp., Northfield Laboratories Inc., Sanguine Biosciences, and Therapure Biopharma Inc.

Report Scope

The report provides a detailed overview of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status and the potential commercial market for artificial blood products. The report includes a discussion of artificial oxygen carrier products manufacturing, product features, technology and methodology used, available results of laboratory and clinical tests, product effectiveness, and factors that are affecting the market. Further, it explains the major drivers and regional dynamics of the global artificial blood market and current trends within the industry.

The report concludes with a special look at the potential artificial blood products that may enter the blood market postapproval from international authorities. Detailed profiles of the key players in the global artificial blood market and the current development stages of their products have been included. Excluded from consideration are product physical and chemical properties, detailed and unpublished clinical/lab results on the products, and detailed methodology/techniques used for product production.

Analyst Credentials

Led by Research Head Karthik Arun, the BCC Research staff is composed of expert analysts skilled in conducting primary research, secondary research and data analysis and who have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in microbiology, electrical engineering, business administration, surgery, and other subject areas.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Contribution of the Study and Intended Audience
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analysts' Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

  • Introduction

Chapter 3: Market Overview

  • Introduction
  • Is There a Problem with Human Blood?
  • Emerging Needs for Artificial Blood
    • Artificial Blood Will Be Useful in Dealing with the Risks of Infection
    • Artificial Blood Will Help to Decrease the Load on Donor Blood Supply
    • Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System
    • Artificial Blood Has the Potential to Lower Costs of the Blood System
  • Hurdles in the Development of Artificial Blood Products
  • Ideal Characteristics of Artificial Blood
  • Artificial Blood Over Human Blood
  • Challenges in Artificial Blood Development

Chapter 4: Market Estimation

  • Market Dynamics: Factors and Impact Analysis
    • Time factor
    • Product Preference
    • Regulatory Approvals
    • Product Demand
    • Product Acceptance
    • Cost and Effectiveness
    • Intense Competition in the Market
    • Clinical Trials
    • Technologies
    • Product Pricing
    • Patient Group
  • Global Potential Market
    • Surgeries and Death Cases
  • Market Penetration

Chapter 5: Market by Source

  • Introduction
  • Artificial Blood Developed from Human Blood
  • Artificial Blood Developed from Animal Blood
  • Artificial Blood Developed Using Recombinant Technology
    • Surface Modified Hemoglobin
    • Cross-Linked Hemoglobin
    • Polymerized Hemoglobin

Chapter 6: Market by Type

  • Introduction
  • Perfluorocarbon Emulsions
    • General Characteristics of Perfluorocarbons
    • Emulsion Selection
    • Historical Developments of Perfluorocarbon Emulsions
    • First Generation of PFCs
    • Second Generation of PFCs
    • Third Generation of PFCs
  • Hemoglobin Based Oxygen Carriers
    • General Characteristics of HBOCs
    • Historical Events: - Hemoglobin Solutions

Chapter 7: Market Breakdown by Application

  • Introduction
    • Surgeries
    • Emergency Resuscitation
    • For Short-term Use
    • Where More Effective Than Human Blood
    • Rejections Due to Religious Beliefs
  • Global Potential Artificial Blood Market, by Application

Chapter 8: Market Breakdown by Region

  • Introduction
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
  • Rest of The World
    • Brazil
    • South Africa

Chapter 9: Regulation and Patent Review

  • Introduction
  • FDA Regulation
  • FDA Good Manufacturing Practices and Reporting
  • Patent Review

Chapter 10: Competitive Landscape

  • Introduction

Chapter 11: Product Analysis

  • Introduction
    • Product Safety
    • Product Effectiveness
    • Product Cost
    • Legal Implications
  • Hemolink
    • Product offered by Hemosol BioPharma Inc.
    • Clinical Trials
  • HemAssist
    • Product offered by Baxter Healthcare Corp.
  • Hemopure
    • Product offered by Biopure Corp./OPK Biotech
    • Clinical Trials
  • HemoSpan
    • Product offered by Sangart, Inc.
    • Clinical Trials
  • HemoTech
    • Product offered by HemoBioTech, Inc.
    • Clinical Trials
  • DDFPe
    • Product offered by NuvOx Pharma LLC
    • Clinical Trials
  • Oxycyte
    • Product offered by Tenax Therapeutics, Inc.
    • Clinical Trials
  • Oxygent
    • Product offered by Alliance Pharmaceutical Corp.
    • Clinical Trials
  • Vidaphor
    • Product offered by FluorO2 Therapeutics, Inc.
    • Clinical Trials
  • PHER-O2
    • Product offered by Sanguine Biosciences
    • Clinical Trials
  • Polyheme
    • Product Offered by Northfield Laboratories Inc.
    • Clinical Trials
  • Sanguinate
    • Product Offered by Prolong Pharmaceuticals, LLC
    • Clinical Trials

Chapter 12: Company Profiles

Appendix

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research
Back to Top